Both in Pharmaceuticals
Monopar Therapeutics vs Gyre Therapeutics
Over the past year MNPR returned −17.9% and GYRE returned −40.5%; their daily moves had a correlation of 0.14.
MNPR −17.9% GYRE −40.5%Growth of $1, one year, split-adjusted
| Metric | MNPR | GYRE |
|---|---|---|
| Price | $70.32 | $4.56 |
| Market cap | $472.0M | $483.0M |
| Today | −2.21% | −28.94% |
| 1 month | −9.8% | −34.9% |
| 6 months | +32.1% | −41.6% |
| Year to date | +7.7% | −35.5% |
| 1 year | −16.4% | −39.6% |
| Revenue growth (YoY) | — | −2.1% |
| Gross margin | — | 92.4% |
| Net margin | — | −40.1% |
| P/E (TTM) | — | — |
| Price / sales | — | 4.0× |
| Net cash | $134.3M | $74.8M |
| Dividend yield | — | — |
| Volatility (60d) | 49.1% | 87.6% |
| Short % of float | 23.3% | 11.5% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).